The first patients have received Diakonos Oncology’s DOC1021, or dubodencel, in a Phase 1/2 trial for unresectable or metastatic melanoma that has progressed after previous treatment, including anti-PD-1 immunotherapy. Treatment has begun at City of Hope in California and the University of Alabama at Birmingham, with additional United States cancer centres recruiting participants. Diakonos reported no significant acute adverse events among the first treated patients, but the company has not disclosed the number treated, follow-up duration or detailed safety findings, and no melanoma efficacy results are available yet.
DOC1021 is manufactured individually using a patient’s own dendritic cells and tumour material. The therapy is designed to expose the immune system to a broad collection of antigens from that patient’s cancer without genetically engineering the immune cells or requiring the lymphodepleting chemotherapy and high-dose interleukin-2 used with some other personalised cellular therapies. Initial safety, immune-biomarker and clinical-activity results are expected during the fourth quarter of 2026.
How DOC1021 uses tumour lysate and mRNA to create an individualised immune response
Dendritic cells are immune cells that capture antigens and present them to T cells, helping the immune system identify which targets should be attacked. DOC1021 attempts to use this antigen-presenting function to generate a personalised response against multiple components of an individual patient’s melanoma rather than relying on one predetermined tumour marker.
Eligible patients must provide tumour material through a biopsy or surgical resection. The trial requires at least 50 milligrams of tissue and preferably 100 milligrams to manufacture the therapy, while leaving at least one measurable lesion that can be followed through imaging under RECIST 1.1 response criteria. Participants must also undergo leukapheresis after receiving five doses of filgrastim to collect the blood cells needed for production.
Diakonos describes DOC1021 as “double-loaded” because the patient’s dendritic cells are exposed to both tumour lysate and amplified tumour-derived messenger RNA. Tumour lysate contains proteins and other material released from disrupted cancer cells, while the RNA component is intended to support production and presentation of additional tumour antigens. The company’s objective is to expose T cells to a wider antigen repertoire than a therapy directed at one mutation or protein.
A broad antigen strategy may be relevant after checkpoint-inhibitor failure because melanomas can contain genetically different cell populations and may escape treatment by reducing or changing individual immune targets. Presenting numerous patient-specific antigens could theoretically reduce the likelihood that every malignant cell avoids recognition through the same mechanism.
That possibility remains a scientific hypothesis in refractory melanoma. Diakonos has reported antitumour activity in preclinical models, including the B16F10 melanoma model, but animal results cannot predict the response rate, duration of benefit or safety profile in people whose disease has progressed after modern immunotherapy.
Unlike CAR-T and genetically modified T-cell receptor therapies, DOC1021 does not introduce a synthetic receptor into the patient’s immune cells. Its success instead depends on the manufactured dendritic cells presenting relevant tumour antigens strongly enough to activate an effective T-cell response within a patient whose cancer has already resisted previous immune treatment.
The 35-patient DOC-RM study begins with safety before moving into single-arm efficacy testing
DOC-RM is expected to enroll 35 adults with unresectable or metastatic melanoma. Participants must have experienced disease progression after at least one systemic regimen that included an anti-PD-1 therapy. Patients with previously treated and stable brain metastases may participate, while eligible patients must generally have an Eastern Cooperative Oncology Group performance status of zero or one and adequate organ and bone-marrow function.
The trial begins with a Phase 1 component intended to confirm the safety and tolerability of the treatment regimen. A subsequent single-arm Phase 2 cohort will evaluate preliminary efficacy without a concurrent control group. The study is divided into three treatment groups, although the available public summaries do not provide complete details about how the 35 participants will be distributed among them.
Each participant receives two image-guided DOC1021 injections approximately two weeks apart near regional lymph nodes. Pegylated interferon alfa-2a is administered subcutaneously once weekly for four doses alongside the initial treatment course. Patients may receive an optional image-guided DOC1021 booster about six months after the first dose, accompanied by two additional pegylated interferon injections.
Pegylated interferon is included to support immune activation, meaning DOC-RM is evaluating a treatment regimen rather than DOC1021 in isolation. Investigators will need to distinguish adverse events associated with the dendritic cell product from those caused by filgrastim, leukapheresis, tumour collection, image-guided injections or interferon.
The study’s endpoints include safety, objective tumour response, circulating tumour DNA and immune biomarkers measured in blood and tumour tissue. Circulating tumour DNA may provide an early molecular indication that tumour burden is changing, while immune analyses can show whether DOC1021 activates tumour-reactive T cells. Neither biomarker is a substitute for demonstrating durable tumour shrinkage, delayed progression or improved survival.
Patients may also receive optional anti-PD-1 treatment during later follow-up. That flexibility may reflect real-world clinical needs and allow investigators to explore whether DOC1021 re-sensitises tumours to checkpoint inhibition. It could complicate interpretation if responses occur after both therapies have been administered, particularly within a small, uncontrolled trial.
The company is enrolling patients at centres including City of Hope, the University of Alabama at Birmingham, Massachusetts General Hospital, Banner MD Anderson Cancer Center, UT Southwestern, HonorHealth Research Institute, the University of North Carolina and Atlantic Health. The program is supported partly by a Product Development Research Grant from the Cancer Prevention and Research Institute of Texas.
Outpatient treatment could avoid the intensive conditioning required with lifileucel
Patients whose unresectable or metastatic melanoma progresses after PD-1 inhibition have limited options. Available approaches can include another checkpoint-inhibitor combination, mutation-targeted therapy for eligible tumours, clinical trials or personalised cell therapy. The FDA approved lifileucel as the first tumour-derived cellular therapy for previously treated unresectable or metastatic melanoma in 2024.
Lifileucel is manufactured by expanding T cells collected from surgically removed tumour tissue. Its approved regimen requires lymphodepleting chemotherapy with cyclophosphamide and fludarabine before the cell infusion, followed by as many as six doses of high-dose interleukin-2. It must be administered in a hospital with intensive-care capability because of risks that include treatment-related death, prolonged low blood counts, severe infection and cardiopulmonary or renal complications.
The therapy produced a 31.5% objective response rate among 73 patients treated within the recommended dose range, including complete responses in 4.1% and partial responses in 27.4%. Those results provide an important benchmark for any new cellular therapy entering the post-PD-1 melanoma setting, although cross-trial comparisons will remain unreliable because of differences in patient selection and treatment history.
DOC1021 is intended to offer a less intensive treatment experience. Diakonos says it does not require lymphodepleting chemotherapy, genetic engineering or high-dose interleukin-2 and can be administered in an outpatient setting. Avoiding those components could reduce hospitalisation, severe cytopenias, infection risk and the specialised infrastructure required for treatment.
Outpatient administration should not be confused with a simple off-the-shelf injection. DOC1021 remains a personalised product that requires tumour procurement, filgrastim injections, leukapheresis, patient-specific manufacturing and image-guided administration near lymph nodes. Successful commercial use would depend on reliable production, treatment scheduling and coordination between surgical, oncology and cell-processing teams.
The product must also demonstrate enough antitumour activity to justify that complexity. A safer and less intensive regimen would be clinically valuable, but a substantially lower response rate or short-lived disease control could limit its role when an approved cellular treatment is available.
Initial fourth-quarter findings will be preliminary and cannot establish melanoma efficacy
Diakonos expects to release initial safety, biomarker and clinical-activity results during the fourth quarter of 2026. The timing indicates that the first update is likely to involve a small number of participants with limited follow-up. Early reports may show whether treatment can be manufactured and administered, whether acute toxicities emerge and whether immune or circulating tumour DNA changes occur.
The company’s statement that the first patients experienced no significant acute adverse events is encouraging but incomplete. It does not reveal the number of doses administered, whether lower-grade reactions occurred, how adverse events were graded or whether delayed immune effects developed. Dendritic cell immunotherapy and pegylated interferon could produce systemic immune symptoms that may become clearer as additional participants are treated.
Tumour response will require sufficient imaging follow-up. Apparent immune-related tumour enlargement can occasionally occur before regression, while delayed responses may be difficult to distinguish from continued disease progression in patients with aggressive metastatic melanoma. Investigators should report conventional RECIST results, duration of response, progression-free survival and the timing of any subsequent anti-PD-1 treatment.
The Phase 2 component’s single-arm design will limit the conclusions that can be drawn even if responses are observed. Objective tumour shrinkage is less vulnerable to bias than symptom reporting, but the study will not directly show that DOC1021 outperforms another treatment. Responses must be interpreted against historical outcomes in carefully matched post-PD-1 populations.
DOC1021 received FDA Fast Track designation for unresectable or metastatic cutaneous melanoma in May 2026. The designation can provide more frequent communication with the FDA and potential eligibility for rolling review or other expedited mechanisms when the relevant requirements are met. It is not an approval and may be granted on the basis of early or preclinical evidence.
Diakonos is also evaluating DOC1021 in glioblastoma and pancreatic cancer. Experience from those programs may provide information about manufacturing, immune activation and general tolerability, but it cannot establish effectiveness in melanoma. Tumour biology, treatment combinations and clinical endpoints differ substantially between the three diseases.
The start of dosing moves DOC1021 from a preclinical melanoma concept into human evaluation. The differentiated feature is not yet proven efficacy, but the attempt to deliver personalised, multi-antigen cell therapy without lymphodepletion, high-dose interleukin-2 or inpatient administration. The first meaningful test will be whether that lower-intensity approach can produce measurable and durable tumour responses in patients whose melanoma has already resisted checkpoint inhibition.
.
